Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | FPR1 | P21462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7964582 | 1.00 | CYP11B2 (0.43) | CYP11B2KCNH2MKNK1MKNK2F7 | |
| SCHEMBL7964580 | 1.00 | CYP11B2 (0.43) | CYP11B2KCNH2MKNK1MKNK2F7 | |
| SCHEMBL8325325 | 0.90 | CYP11B2 (0.39) | CYP11B2KCNH2MKNK1MKNK2FPR1 | |
| SCHEMBL7967732 | 0.89 | CYP11B2 (0.39) | CYP11B2KCNH2FPR1FPR2ALDH1A1 | |
| SCHEMBL7964715 | 0.87 | CYP11B2 (0.43) | CYP11B2KCNH2MKNK1MKNK2F7 | |
| SCHEMBL7962101 | 0.86 | NR4A2 (0.40) | CYP11B2FPR1FPR2ALDH1A1 | |
| SCHEMBL2157354 | 0.85 | MKNK1 (0.39) | CYP11B2KCNH2MKNK1MKNK2ATM | |
| SCHEMBL7952126 | 0.85 | CYP11B2 (0.41) | CYP11B2MKNK1MKNK2ALDH1A1 | |
| SCHEMBL7963297 | 0.84 | MKNK1 (0.42) | CYP11B2MKNK1MKNK2CSNK1DCSNK1E | |
| SCHEMBL7962238 | 0.84 | CYP11B2 (0.41) | CYP11B2KCNH2MKNK1MKNK2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6207675-B1 | FOR PROPHYLAXIS AND THERAPY OF DISEASES IN WHICH ARE INVOLVED VIRUSES OF THE HERPES FAMILY AND/OR CYTOKINES IN PARTICULAR TUMOR NERCOSIS FACTOR-ALPHA | RHONE-POULENC RORER S.A. (FR) | 2001-03-27 | — | — | US | claimed |
| EP-0946555-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1999-10-06 | — | — | EP | claimed |
| WO-1998025925-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1998-06-18 | — | — | WO | claimed |
| EP-2361253-A1 | COMPOUNDS | Selcia Limited (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-20110184011-A1 | Compounds | SELCIA LIMITED (GB) | 2011-07-28 | — | — | US | disclosed |
| WO-2010029364-A1 | COMPOUNDS | SELCIA LIMITED (GB) | 2010-03-18 | — | — | WO | disclosed |
| US-6207675-B1 | FOR PROPHYLAXIS AND THERAPY OF DISEASES IN WHICH ARE INVOLVED VIRUSES OF THE HERPES FAMILY AND/OR CYTOKINES IN PARTICULAR TUMOR NERCOSIS FACTOR-ALPHA | RHONE-POULENC RORER S.A. (FR) | 2001-03-27 | — | — | US | disclosed |
| EP-0946555-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998025925-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184011-A1 | Compounds | COL1A1, ALDH1A2, COL2A1 | CYP11B2 164/4885KCNH2 3656/4885MKNK1 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.